CA-HIGHWIRE
21.4.2020 14:32:07 CEST | Business Wire | Press release
Scholarly publishing technology provider, HighWire, is working with Cloudflare Inc., the security, performance, and reliability company helping to build a better Internet, to ensure that the world’s information stays online, accessible and responsive during the COVID-19 global pandemic.
HighWire customers across the board are seeing heightened traffic, successfully serving nearly 25 million more requests in March than in January while remaining highly responsive. HighWire hosts sites and medical journals for key information providers including BMJ, Science Magazine, The World Health Organization and bioRxiv / medRxiv, all of which are currently experiencing record levels of traffic. As preprint repositories, medRxiv and bioRxiv in particular are playing a key role in rapidly sharing knowledge in a fluid landscape, with both rendering over 15M unique page views during the month of March, up from a monthly average of 4M for bioRxiv and 1M for medRxiv.
With traffic to some HighWire hosted journals surging by almost sevenfold, and some individual articles attracting over 4 million unique pageviews, a robust resilience plan is critical to ensuring that the global research community can access information and point-of-care resources during this crisis. HighWire’s infrastructure maintains a 99.9% uptime rate, and has carried out a number of performance tuning measures over recent years to provide surge capacity.
For such unprecedented levels of traffic, HighWire leverages Cloudflare to isolate requests for new research which is trending globally. Access to any highly requested page or document can be offloaded to Cloudflare to ensure traffic surges are absorbed and the remainder of site function is not impacted. Additionally, Cloudflare constantly scans traffic for malicious attacks and requests, provides zero day protection for security breaches, and operates multiple points of presence through the Cloudflare Global Anycast Network— all of which allows for larger assets to be served locally at a distributed level, reducing server load and increasing speed while eliminating multiple points of failure.
“At a time where many online resources are experiencing load-related disruptions in services, we are proud that HighWire’s technology and services have proven so reliable at this time, absorbing traffic levels of 2-6x the standard while continuing to serve end-users with no change in uptime or response time,” said Todd McGee, VP of Research, Development and Operations, “Having a robust and reliable high availability strategy is paramount, which is why HighWire has put considerable time and resources into developing this over the past few years in order to provide our customers with a stable service that bolsters the community.”
About HighWire
HighWire is a global provider of digital publishing solutions and platform expertise across all aspects of the publishing life cycle, including content management and hosting, e-commerce, analytics, access and identity management, manuscript submission and tracking.
Born out of Stanford University and now celebrating its 25th year, HighWire is backed by Stanford and private equity firm Accel-KKR, recently listed as the top founder-friendly investors for entrepreneurial partnership. This combination of deep digital understanding, academic expertise and strong financial backing makes HighWire the technology partner of choice for world-leading commercial and academic publishers.
For more information, please visit highwirepress.com and follow us on Twitter , LinkedIn and Facebook .
About Cloudflare
Cloudflare, Inc. is on a mission to help build a better Internet. Cloudflare’s platform protects and accelerates any Internet application online without adding hardware, installing software, or changing a line of code. Internet properties powered by Cloudflare have all web traffic routed through its intelligent global network, which gets smarter with every request. As a result, they see significant improvement in performance and a decrease in spam and other attacks. Cloudflare was named to Entrepreneur Magazine’s Top Company Cultures 2018 list and ranked among the World’s Most Innovative Companies by Fast Company in 2019. Headquartered in San Francisco, CA, Cloudflare has offices in Austin, TX, Champaign, IL, New York, NY, San Jose, CA, Seattle, WA, Washington, D.C., Lisbon, London, Munich, Beijing, Singapore, and Sydney.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200421005039/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
